WHAT IS CLAIMED IS DESCRIBED BELOW:

1. A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is an indazole nonpeptide, and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and chelator.

2. A compound according to Claim 1, wherein the receptor is the integrin $\alpha_v\beta_3$ or $\alpha_v\beta_5$ and the compound is of the formula:

$$(Q)_d\text{-}L_n\text{-}C_h \text{ or } (Q)_d\text{-}L_n\text{-}(C_h)_d,$$

wherein, Q is independently a compound of Formula (Ia) or (Ib):



(Ia)



(Ib)

including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein:

X^{1d} is N, CH, C-W^d-X^d-Y^d, or C-L_n;

X^{2d} is N, CH, or C-W^d-X^d-Y^d;

X^{3d} is N, CR^{11d}, or C-W^d-X^d-Y^d;

X^{4d} is N or CR^{11d};

provided that when R^{1d} is R^{1de} then one of X^{1d} and X^{2d} is C-W^d-X^d-Y^d, and when R^{10d} is R^{1de} then X^{3d} is C-W^d-X^d-Y^d;

R^{1d} is selected from: R^{1de}, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_6 alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{1de} is selected from:



or

;

A^d and B^d are independently $-CH_2-$, $-O-$, $-N(R^{2d})-$, or $-C(=O)-$;

A^{1d} and B^{1d} are independently $-CH_2-$ or $-N(R^{3d})-$;

D^d is $-N(R^{2d})-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E^d-F^d is $-C(R^{4d})=C(R^{5d})-$, $-N=C(R^{4d})-$, $-C(R^{4d})=N-$, or $-C(R^{4d})_2C(R^{5d})_2-$;

J^d, K^d, L^d and M^d are independently selected from $-C(R^{4d})-$, $-C(R^{5d})-$ and $-N-$, provided that at least one of J^d, K^d, L^d and M^d is not $-N-$;

R^{2d} is selected from: H, C_1-C_6 alkyl, (C_1-C_6 alkyl)carbonyl, (C_1-C_6 alkoxy)carbonyl; (C_1-C_6 alkyl)aminocarbonyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, heteroaryl(C_1-C_6 alkyl)carbonyl, heteroarylcarbonyl, aryl(C_1-C_6 alkyl)-, (C_1-C_6 alkyl)carbonyl-, arylcarbonyl, C_1-C_6 alkylsulfonyl, arylsulfonyl, aryl(C_1-C_6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C_1-C_6 alkyl)sulfonyl, aryloxycarbonyl, and aryl(C_1-C_6 alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group: C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, CF_3, and nitro;

R^{3d} is selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_1-C_6 alkyl)-;

R^{4d} and R^{5d} are independently selected from: H, C_1-C_4 alkoxy, $NR^{2d}R^{3d}$, halogen, NO_2, CN, CF_3, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, (C_1-C_6

alkyl)carbonyl, (C_1-C_6 alkoxy)carbonyl, and arylcarbonyl, or

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, cyano, amino, CF_3, and NO_2;

U^d is selected from:

$-(CH_2)_n{}^d-$,

$-(CH_2)_n{}^d(CR^{7d}=CR^{8d})(CH_2)_m{}^d-$,

$-(CH_2)_n{}^d(C\equiv C)(CH_2)_m{}^d-$,

$-(CH_2)_t{}^dQ(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dO(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dN(R^{6d})(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dC(=O)(CH_2)_m{}^d-$,

$-(CH_2)_n{}^d(C=O)N(R^{6d})(CH_2)_m{}^d-$

$-(CH_2)_n{}^dN(R^{6d})(C=O)(CH_2)_m{}^d-$, and

$-(CH_2)_n{}^dS(O)_p{}^d(CH_2)_m{}^d-$;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d};

Q^d is selected from 1,2-cycloalkylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,3-pyridinylene, 3,4-pyridinylene, 2,4-pyridinylene, and 3,4-pyridazinylene;

R^{6d} is selected from: H, C_1-C_4 alkyl, and benzyl;

R^{7d} and R^{8d} are independently selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_0-C_6 alkyl)-;

R^{10d} is selected from: H, R^{1de}, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, $N(R^{6d})_2$, halogen, NO_2, CN, CF_3, CO_2R^{17d}, $C(=O)R^{17d}$, $CONR^{17d}R^{20d}$, $-SO_2R^{17d}$, $-SO_2NR^{17d}R^{20d}$, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_6 alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{10de} is selected from: H, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, $N(R^{6d})_2$, halogen, NO_2, CN, CF_3, CO_2R^{17d}, $C(=O)R^{17d}$, $CONR^{17d}R^{20d}$, $-SO_2R^{17d}$, $-SO_2NR^{17d}R^{20d}$, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_6 alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{11d} is selected from H, halogen, CF_3, CN, NO_2, hydroxy, $NR^{2d}R^{3d}$, C_1-C_4 alkyl substituted with 0-1 R^{21d}, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, aryl substituted with 0-1 R^{21d}, aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{21d}, (C_1-C_4 alkoxy)carbonyl substituted with 0-1 R^{21d}, (C_1-C_4 alkyl)carbonyl substituted with 0-1 R^{21d},

C_1-C_4 alkylsulfonyl substituted with 0-1 R^{21d}, and
C_1-C_4 alkylaminosulfonyl substituted with 0-1 R^{21d};

W^d is selected from:
$-(C(R^{12d})_2)_q{}^dC(=O)N(R^{13d})-$, and
$-C(=O)-N(R^{13d})-(C(R^{12d})_2)_q{}^d-$;

X^d is $-C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-$; or
alternatively, W^d and X^d can be taken together to be



;

R^{12d} is selected from H, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, C_4-C_{10} cycloalkylalkyl, (C_1-C_4 alkyl)carbonyl, aryl, and aryl(C_1-C_6 alkyl)-;

R^{13d} is selected from H, C_1-C_6 alkyl, C_3-C_7 cycloalkylmethyl, and aryl(C_1-C_6 alkyl)-;

R^{14d} is selected from:
H, C_1-C_6 alkylthio(C_1-C_6 alkyl)-, aryl(C_1-C_{10} alkylthioalkyl)-, aryl(C_1-C_{10} alkoxyalkyl)-, C_1-C_{10} alkyl, C_1-C_{10} alkoxyalkyl, C_1-C_6 hydroxyalkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl(C_1-C_6 alkyl)-, heteroaryl(C_1-C_6 alkyl)-, aryl, heteroaryl, CO_2R^{17d}, $C(=O)R^{17d}$, and $CONR^{17d}R^{20d}$, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R^{16d} or 0-2 R^{11d};

R^{15d} is selected from:

H, R^{16d}, C_1-C_{10} alkyl, C_1-C_{10} alkoxyalkyl, C_1-C_{10} alkylaminoalkyl, C_1-C_{10} dialkylaminoalkyl, (C_1-C_{10} alkyl)carbonyl, aryl(C_1-C_6 alkyl)carbonyl, C_1-C_{10} alkenyl, C_1-C_{10} alkynyl ,C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl(C_1-C_6 alkyl)-, heteroaryl(C_1-C_6 alkyl)-, aryl, heteroaryl, CO_2R^{17d}, $C(=O)R^{17d}$, $CONR^{17d}R^{20d}$, SO_2R^{17d}, and $SO_2NR^{17d}R^{20d}$, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R^{11d};

Y^d is selected from:

$-COR^{19d}$, $-SO_3H$, $-PO_3H$, tetrazolyl, $-CONHNHSO_2CF_3$, $-CONHSO_2R^{17d}$, $-CONHSO_2NHR^{17d}$, $-NHCOCF_3$, $-NHCONHSO_2R^{17d}$, $-NHSO_2R^{17d}$, $-OPO_3H_2$, $-OSO_3H$, $-PO_3H_2$, $-SO_3H$, $-SO_2NHCOR^{17d}$, $-SO_2NHCO_2R^{17d}$,


,

, and

;

R^{16d} is selected from:

$-N(R^{20d})-C(=O)-O-R^{17d}$,

$-N(R^{20d})-C(=O)-R^{17d}$,

$-N(R^{20d})-C(=O)-NH-R^{17d}$,

$-N(R^{20d})SO_2-R^{17d}$, and

$-N(R^{20d})SO_2-NR^{20d}R^{17d}$;

R^{17d} is selected from:

C_1-C_{10} alkyl optionally substituted with a bond to L_n, C_3-C_{11} cycloalkyl optionally substituted with a bond to L_n, aryl(C_1-C_6 alkyl)- optionally substituted

with a bond to L_n, (C_1-C_6 alkyl)aryl optionally substituted with a bond to L_n, heteroaryl(C_1-C_6 alkyl)- optionally substituted with a bond to L_n, (C_1-C_6 alkyl)heteroaryl optionally substituted with a bond to L_n, biaryl(C_1-C_6 alkyl)- optionally substituted with a bond to L_n, heteroaryl optionally substituted with a bond to L_n, aryl optionally substituted with a bond to L_n, biaryl optionally substituted with a bond to L_n, and a bond to L_n, wherein said aryl, biaryl or heteroaryl groups are also optionally substituted with 0-3 substituents selected from the group consisting of: C_1-C_4 alkyl, C_1-C_4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF_3, and NO_2;

R^{18d} is selected from:
-H,
$-C(=O)-O-R^{17d}$,
$-C(=O)-R^{17d}$,
$-C(=O)-NH-R^{17d}$,
$-SO_2-R^{17d}$, and
$-SO_2-NR^{20d}R^{17d}$;

R^{19d} is selected from: hydroxy, C_1-C_{10} alkyloxy, C_3-C_{11} cycloalkyloxy, aryloxy, aryl(C_1-C_6 alkoxy)-, C_3-C_{10} alkylcarbonyloxyalkyloxy, C_3-C_{10} alkoxycarbonyloxyalkyloxy, C_2-C_{10} alkoxycarbonylalkyloxy, C_5-C_{10} cycloalkylcarbonyloxyalkyloxy, C_5-C_{10} cycloalkoxycarbonyloxyalkyloxy, C_5-C_{10} cycloalkoxycarbonylalkyloxy, C_7-C_{11} aryloxycarbonylalkyloxy, C_8-C_{12} aryloxycarbonyloxyalkyloxy, C_8-C_{12} arylcarbonyloxyalkyloxy,

C_5-C_{10} alkoxyalkylcarbonyloxyalkyloxy, C_5-C_{10} (5-alkyl-1,3-dioxa-cyclopenten-2-one-yl)methyloxy, C_{10}-C_{14} (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyloxy, and $(R^{11d})(R^{12d})N$-(C_1-C_{10} alkoxy)-;

R^{20d} is selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_1-C_6 alkyl)-;

R^{21d} is selected from: COOH and NR^{6d}_2;

m^d is 0-4;

n^d is 0-4;

t^d is 0-4;

p^d is 0-2;

q^d is 0-2; and

r^d is 0-2;

with the following provisos:

(1) t^d, n^d, m^d and q^d are chosen such that the number of atoms connecting R^{1d} and Y^d is in the range of 10-14; and

(2) n^d and m^d are chosen such that the value of n^d plus m^d is greater than one unless U^d is $-(CH_2)_t{}^d Q^d (CH_2)_m{}^d-$;

or Q is a peptide selected from the group:



and



;

R^1 is L-valine, D-valine or L-lysine optionally substituted on the ε amino group with a bond to L_n;

R^2 is L-phenylalanine, D-phenylalanine, D-1-naphthylalanine, 2-aminothiazole-4-acetic acid or tyrosine, the tyrosine optionally substituted on the hydroxy group with a bond to L_n;

R^3 is D-valine;

R^4 is D-tyrosine substituted on the hydroxy group with a bond to L_n;

provided that one of R^1 and R^2 in each Q is substituted with a bond to L_n, and further provided that when R^2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine;

provided that at least one Q is a compound of Formula (Ia) or (Ib);

d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

d' is 1-100;

L_n is a linking group having the formula:

$((W)_h-(CR^6R^7)_g)_x-(Z)_k-((CR^{6a}R^{7a})_{g'}-(W)_{h'})_{x'}$;

W is independently selected at each occurrence from the group: O, S, NH, NHC(=O), C(=O)NH, $NR^8C(=O)$, C(=O)N

R^8, C(=O), C(=O)O, OC(=O), NHC(=S)NH, NHC(=O)NH, SO_2, SO_2NH, $(OCH_2CH_2)_s$, $(CH_2CH_2O)_{s'}$, $(OCH_2CH_2CH_2)_{s''}$, $(CH_2CH_2CH_2O)_t$, and $(aa)_{t'}$;

aa is independently at each occurrence an amino acid;

Z is selected from the group: aryl substituted with 0-3 R^{10}, C_{3-10} cycloalkyl substituted with 0-3 R^{10}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{10};

R^6, R^{6a}, R^7, R^{7a}, and R^8 are independently selected at each occurrence from the group: H, =O, COOH, SO_3H, PO_3H, C_1-C_5 alkyl substituted with 0-3 R^{10}, aryl substituted with 0-3 R^{10}, benzyl substituted with 0-3 R^{10}, and C_1-C_5 alkoxy substituted with 0-3 R^{10}, $NHC(=O)R^{11}$, $C(=O)NHR^{11}$, $NHC(=O)NHR^{11}$, NHR^{11}, R^{11}, and a bond to C_h;

R^{10} is independently selected at each occurrence from the group: a bond to C_h, $COOR^{11}$, $C(=O)NHR^{11}$, $NHC(=O)R^{11}$, OH, NHR^{11}, SO_3H, PO_3H, $-OPO_3H_2$, $-OSO_3H$, aryl substituted with 0-3 R^{11}, C_{1-5} alkyl substituted with 0-1 R^{12}, C_{1-5} alkoxy substituted with 0-1 R^{12}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{11};

R^{11} is independently selected at each occurrence from the group: H, alkyl substituted with 0-1 R^{12}, aryl substituted with 0-1 R^{12}, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and

substituted with 0-1 R^{12}, C_{3-10} cycloalkyl substituted with 0-1 R^{12}, polyalkylene glycol substituted with 0-1 R^{12}, carbohydrate substituted with 0-1 R^{12}, cyclodextrin substituted with 0-1 R^{12}, amino acid substituted with 0-1 R^{12}, polycarboxyalkyl substituted with 0-1 R^{12}, polyazaalkyl substituted with 0-1 R^{12}, and peptide substituted with 0-1 R^{12}, wherein the peptide is comprised of 2-10 amino acids, 3,6-O-disulfo-B-D-galactopyranosyl, bis(phosphonomethyl)glycine, and a bond to C_h;

R^{12} is a bond to C_h;

k is selected from 0, 1, and 2;
h is selected from 0, 1, and 2;
h' is selected from 0, 1, and 2;
g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
g' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
s is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
s' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
s" is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
t is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
t' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
x is selected from 0, 1, 2, 3, 4, and 5;
x' is selected from 0, 1, 2, 3, 4, and 5;

C_h is a metal bonding unit having a formula selected from the group:



,



,



, and



;

A^1, A^2, A^3, A^4, A^5, A^6, A^7, and A^8 are independently selected at each occurrence from the group: NR^{13}, $NR^{13}R^{14}$, S, SH, S(Pg), O, OH, PR^{13}, $PR^{13}R^{14}$, $P(O)R^{15}R^{16}$, and a bond to L_n;

E is a bond, CH, or a spacer group independently selected at each occurrence from the group: C_1-C_{10} alkyl substituted with 0-3 R^{17}, aryl substituted with 0-3 R^{17}, C_{3-10} cycloalkyl substituted with 0-3 R^{17}, heterocyclo-C_{1-10} alkyl substituted with 0-3 R^{17}, wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C_{6-10} aryl-C_{1-10} alkyl substituted with 0-3 R^{17}, C_{1-10} alkyl-C_{6-10} aryl- substituted with 0-3 R^{17}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{17};

R^{13} and R^{14} are each independently selected from the group: a bond to L_n, hydrogen, C_1-C_{10} alkyl substituted with 0-3 R^{17}, aryl substituted with 0-3 R^{17}, C_{1-10} cycloalkyl substituted with 0-3 R^{17}, heterocyclo-C_{1-10} alkyl substituted with 0-3 R^{17},

wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C_{6-10} aryl-C_{1-10} alkyl substituted with 0-3 R^{17}, C_{1-10} alkyl-C_{6-10} aryl- substituted with 0-3 R^{17}, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{17}, and an electron, provided that when one of R^{13} or R^{14} is an electron, then the other is also an electron;

alternatively, R^{13} and R^{14} combine to form $=C(R^{20})(R^{21})$;

R^{15} and R^{16} are each independently selected from the group: a bond to L_n, -OH, C_1-C_{10} alkyl substituted with 0-3 R^{17}, C_1-C_{10} alkyl substituted with 0-3 R^{17}, aryl substituted with 0-3 R^{17}, C_{3-10} cycloalkyl substituted with 0-3 R^{17}, heterocyclo-C_{1-10} alkyl substituted with 0-3 R^{17}, wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C_{6-10} aryl-C_{1-10} alkyl substituted with 0-3 R^{17}, C_{1-10} alkyl-C_{6-10} aryl- substituted with 0-3 R^{17}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{17};

R^{17} is independently selected at each occurrence from the group: a bond to L_n, =O, F, Cl, Br, I, $-CF_3$, -CN, $-CO_2R^{18}$, $-C(=O)R^{18}$, $-C(=O)N(R^{18})_2$, -CHO, $-CH_2OR^{18}$, $-OC(=O)R^{18}$, $-OC(=O)OR^{18a}$, $-OR^{18}$, $-OC(=O)N(R^{18})_2$, $-NR^{19}C(=O)R^{18}$, $-NR^{19}C(=O)OR^{18a}$, $-NR^{19}C(=O)N(R^{18})_2$,

$-NR^{19}SO_2N(R^{18})_2$, $-NR^{19}SO_2R^{18a}$, $-SO_3H$, $-SO_2R^{18a}$, $-SR^{18}$, $-S(=O)R^{18a}$, $-SO_2N(R^{18})_2$, $-N(R^{18})_2$, $-NHC(=S)NHR^{18}$, $=NOR^{18}$, NO_2, $-C(=O)NHOR^{18}$, $-C(=O)NHNR^{18}R^{18a}$, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy, C_1-C_5 alkyl, C_2-C_4 alkenyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl, C_2-C_6 alkoxyalkyl, aryl substituted with 0-2 R^{18}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O;

R^{18}, R^{18a}, and R^{19} are independently selected at each occurrence from the group: a bond to L_n, H, C_1-C_6 alkyl, phenyl, benzyl, C_1-C_6 alkoxy, halide, nitro, cyano, and trifluoromethyl;

Pg is a thiol protecting group;

R^{20} and R^{21} are independently selected from the group: H, C_1-C_{10} alkyl, -CN, $-CO_2R^{25}$, $-C(=O)R^{25}$, $-C(=O)N(R^{25})_2$, C_2-C_{10} 1-alkene substituted with 0-3 R^{23}, C_2-C_{10} 1-alkyne substituted with 0-3 R^{23}, aryl substituted with 0-3 R^{23}, unsaturated 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{23}, and unsaturated C_{3-10} carbocycle substituted with 0-3 R^{23};

alternatively, R^{20} and R^{21}, taken together with the divalent carbon radical to which they are attached form:



R^{22} and R^{23} are independently selected from the group: H, R^{24}, C_1-C_{10} alkyl substituted with 0-3 R^{24}, C_2-C_{10} alkenyl substituted with 0-3 R^{24}, C_2-C_{10} alkynyl substituted with 0-3 R^{24}, aryl substituted with 0-3 R^{24}, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{24}, and C_{3-10} carbocycle substituted with 0-3 R^{24};

alternatively, R^{22}, R^{23} taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O;

a and b indicate the positions of optional double bonds and n is 0 or 1;

R^{24} is independently selected at each occurrence from the group: =O, F, Cl, Br, I, $-CF_3$, -CN, $-CO_2R^{25}$, $-C(=O)R^{25}$, $-C(=O)N(R^{25})_2$, $-N(R^{25})_3^+$, $-CH_2OR^{25}$, $-OC(=O)R^{25}$, $-OC(=O)OR^{25a}$, $-OR^{25}$, $-OC(=O)N(R^{25})_2$, $-NR^{26}C(=O)R^{25}$, $-NR^{26}C(=O)OR^{25a}$, $-NR^{26}C(=O)N(R^{25})_2$, $-NR^{26}SO_2N(R^{25})_2$, $-NR^{26}SO_2R^{25a}$, $-SO_3H$, $-SO_2R^{25a}$, $-SR^{25}$, $-S(=O)R^{25a}$, $-SO_2N(R^{25})_2$, $-N(R^{25})_2$, $=NOR^{25}$, $-C(=O)NHOR^{25}$, $-OCH_2CO_2H$, and 2-(1-morpholino)ethoxy; and,

R^{25}, R^{25a}, and R^{26} are each independently selected at each occurrence from the group: hydrogen and C_1-C_6 alkyl.

3. A compound according to Claim 2, wherein:

R^{1de} is selected from:













or



;

A^d and B^d are independently $-CH_2-$, $-O-$, $-N(R^{2d})-$, or $-C(=O)-$;

A^{1d} and B^{1d} are independently $-CH_2-$ or $-N(R^{3d})-$;

D^d is $-N(R^{2d})-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E^d-F^d is $-C(R^{4d})=C(R^{5d})-$, $-N=C(R^{4d})-$, $-C(R^{4d})=N-$, or $-C(R^{4d})_2C(R^{5d})_2-$;

J^d, K^d, L^d and M^d are independently selected from: $C(R^{4d})-$, $-C(R^{5d})-$ and $-N-$, provided that at least one of J^d, K^d, L^d and M^d is not $-N-$;

R^{2d} is selected from: H, C_1-C_6 alkyl, (C_1-C_6 alkyl)carbonyl, (C_1-C_6 alkoxy)carbonyl, C_1-C_6 alkylaminocarbonyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, heteroaryl(C_1-C_6 alkyl)carbonyl, heteroarylcarbonyl, aryl(C_1-C_6 alkyl)-, (C_1-C_6 alkyl)carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(C_1-C_6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C_1-C_6 alkyl)sulfonyl, aryloxycarbonyl, and aryl(C_1-C_6 alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, CF_3, and nitro;

R^{3d} is selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_1-C_6 alkyl)-;

R^{4d} and R^{5d} are independently selected from: H, C_1-C_4 alkoxy, $NR^{2d}R^{3d}$, halogen, NO_2, CN, CF_3, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11}

cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, C_2-C_7 alkylcarbonyl, and arylcarbonyl;

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, cyano, amino, CF_3, or NO_2;

U^d is selected from:

$-(CH_2)_n^d-$,

$-(CH_2)_n^d(CR^{7d}=CR^{8d})(CH_2)_m^d-$,

$-(CH_2)_t^d Q^d (CH_2)_m^d-$,

$-(CH_2)_n^d O(CH_2)_m^d-$,

$-(CH_2)_n^d N(R^{6d})(CH_2)_m^d-$,

$-(CH_2)_n^d C(=O)(CH_2)_m^d-$, and

$-(CH_2)_n^d S(O)_p^d (CH_2)_m^d-$;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d};

Q^d is selected from 1,2-phenylene, 1,3-phenylene, 2,3-pyridinylene, 3,4-pyridinylene, and 2,4-pyridinylene;

R^{6d} is selected from: H, C_1-C_4 alkyl, and benzyl;

R^{7d} and R^{8d} are independently selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_0-C_6 alkyl)-;

W^d is $-C(=O)-N(R^{13d})-(C(R^{12d})_2)_q^d-$;

X^d is $-C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-$;

alternatively, W^d and X^d can be taken together to be



;

R^{12d} is H or C_1-C_6 alkyl;

Y^d is selected from:

$-COR^{19d}$, $-SO_3H$,



,



, and



;

d is selected from 1, 2, 3, 4, and 5;

d' is 1-50;

W is independently selected at each occurrence from the group: O, NH, NHC(=O), C(=O)NH, $NR^8C(=O)$, C(=O)N R^8, C(=O), C(=O)O, OC(=O), NHC(=S)NH, NHC(=O)NH, SO_2,

$(OCH_2CH_2)_s$, $(CH_2CH_2O)_{s'}$, $(OCH_2CH_2CH_2)_{s''}$, $(CH_2CH_2CH_2O)_t$, and $(aa)_{t'}$;

aa is independently at each occurrence an amino acid;

Z is selected from the group: aryl substituted with 0-1 R^{10}, C_{3-10} cycloalkyl substituted with 0-1 R^{10}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-1 R^{10};

R^6, R^{6a}, R^7, R^{7a}, and R^8 are independently selected at each occurrence from the group: H, =O, COOH, SO_3H, C_1-C_5 alkyl substituted with 0-1 R^{10}, aryl substituted with 0-1 R^{10}, benzyl substituted with 0-1 R^{10}, and C_1-C_5 alkoxy substituted with 0-1 R^{10}, $NHC(=O)R^{11}$, $C(=O)NHR^{11}$, $NHC(=O)NHR^{11}$, NHR^{11}, R^{11}, and a bond to C_h;

k is 0 or 1;
s is selected from 0, 1, 2, 3, 4, and 5;
s' is selected from 0, 1, 2, 3, 4, and 5;
s" is selected from 0, 1, 2, 3, 4, and 5;
t is selected from 0, 1, 2, 3, 4, and 5;

A^1, A^2, A^3, A^4, A^5, A^6, A^7, and A^8 are independently selected at each occurrence from the group: NR^{13}, $NR^{13}R^{14}$, S, SH, S(Pg), OH, and a bond to L_n;

E is a bond, CH, or a spacer group independently selected at each occurrence from the group: C_1-C_{10} alkyl substituted with 0-3 R^{17}, aryl substituted with 0-3 R^{17}, C_{3-10} cycloalkyl substituted with 0-3 R^{17}, and a 5-10 membered heterocyclic ring system containing

1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{17};

R^{13} and R^{14} are each independently selected from the group: a bond to L_n, hydrogen, C_1-C_{10} alkyl substituted with 0-3 R^{17}, aryl substituted with 0-3 R^{17}, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{17}, and an electron, provided that when one of R^{13} or R^{14} is an electron, then the other is also an electron;

alternatively, R^{13} and R^{14} combine to form $=C(R^{20})(R^{21})$;

R^{17} is independently selected at each occurrence from the group: a bond to L_n, =O, F, Cl, Br, I, $-CF_3$, -CN, $-CO_2R^{18}$, $-C(=O)R^{18}$, $-C(=O)N(R^{18})_2$, $-CH_2OR^{18}$, $-OC(=O)R^{18}$, $-OC(=O)OR^{18a}$, $-OR^{18}$, $-OC(=O)N(R^{18})_2$, $-NR^{19}C(=O)R^{18}$, $-NR^{19}C(=O)OR^{18a}$, $-NR^{19}C(=O)N(R^{18})_2$, $-NR^{19}SO_2N(R^{18})_2$, $-NR^{19}SO_2R^{18a}$, $-SO_3H$, $-SO_2R^{18a}$, $-S(=O)R^{18a}$, $-SO_2N(R^{18})_2$, $-N(R^{18})_2$, $-NHC(=S)NHR^{18}$, $=NOR^{18}$, $-C(=O)NHNR^{18}R^{18a}$, $-OCH_2CO_2H$, and 2-(1-morpholino)ethoxy;

R^{18}, R^{18a}, and R^{19} are independently selected at each occurrence from the group: a bond to L_n, H, and C_1-C_6 alkyl;

R^{20} and R^{21} are independently selected from the group: H, C_1-C_5 alkyl, $-CO_2R^{25}$, C_2-C_5 1-alkene substituted with 0-3 R^{23}, C_2-C_5 1-alkyne substituted with 0-3 R^{23}, aryl substituted with 0-3 R^{23}, and unsaturated 5-10 membered heterocyclic ring system containing 1-4

heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{23};

alternatively, R^{20} and R^{21}, taken together with the divalent carbon radical to which they are attached form:



R^{22} and R^{23} are independently selected from the group: H, and R^{24};

alternatively, R^{22}, R^{23} taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O;

R^{24} is independently selected at each occurrence from the group: $-CO_2R^{25}$, $-C(=O)N(R^{25})_2$, $-CH_2OR^{25}$, $-OC(=O)R^{25}$, $-OR^{25}$, $-SO_3H$, $-N(R^{25})_2$, and $-OCH_2CO_2H$; and,

R^{25} is independently selected at each occurrence from the group: H and C_1-C_3 alkyl.

4. A compound according to Claim 3, wherein:

R^{1de} is selected from:



wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group: NH_2,

halogen, NO_2, CN, CF_3, C_1-C_4 alkoxy, C_1-C_6 alkyl, and C_3-C_7 cycloalkyl;

U^d is $-(CH_2)_n-$, $-(CH_2)_t Q^d (CH_2)_m-$ or $-C(=O)(CH_2)_{n-1}-$, wherein one of the methylene groups is optionally substituted with R^{7d};

R^{7d} is selected from: C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl), heteroaryl, and heteroaryl(C_1-C_6 alkyl);

R^{10d} is selected from: H, R^{1de}, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, halogen, CO_2R^{17d}, $CONR^{17d}R^{20d}$, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{10de} is selected from: H, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, halogen, CO_2R^{17d}, $CONR^{17d}R^{20d}$, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

W^d is $-C(=O)-N(R^{13d})-$;

X^d is $-CH(R^{14d})-CH(R^{15d})-$;

R^{13d} is H or CH_3;

R^{14d} is selected from:
H, C_1-C_{10} alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C_1-C_4 alkyl, C_1-C_4 alkoxy, aryl, halo, cyano, amino, CF_3, and NO_2;

R^{15d} is H or R^{16d};

Y^d is $-COR^{19d}$;

R^{19d} is selected from:
hydroxy, C_1-C_{10} alkoxy,
methylcarbonyloxymethoxy-,
ethylcarbonyloxymethoxy-,
t-butylcarbonyloxymethoxy-,
cyclohexylcarbonyloxymethoxy-,
1-(methylcarbonyloxy)ethoxy-,
1-(ethylcarbonyloxy)ethoxy-,
1-(t-butylcarbonyloxy)ethoxy-,
1-(cyclohexylcarbonyloxy)ethoxy-,
i-propyloxycarbonyloxymethoxy-,
t-butyloxycarbonyloxymethoxy-,
1-(i-propyloxycarbonyloxy)ethoxy-,
1-(cyclohexyloxycarbonyloxy)ethoxy-,
1-(t-butyloxycarbonyloxy)ethoxy-,
dimethylaminoethoxy-,
diethylaminoethoxy-,
(5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
(5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
(1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, and
1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;

R^{20d} is H or CH_3;

m^d is 0 or 1;

n^d is 1-4;

t^d is 0 or 1;

C_h is



;

A^1 is selected from the group: OH, and a bond to L_n;

A^2, A^4, and A^6 are each N;

A^3, A^5, and A^8 are each OH;

A^7 is a bond to L_n or NH-bond to L_n;

E is a C_2 alkyl substituted with 0-1 R^{17};

R^{17} is =O;

alternatively, C_h is



;

A^1 is selected from the group: OH and a bond to L_n;

A^2, A^3 and A^4 are each N;

A^5, A^6 and A^8 are each OH;

A^7 is a bond to L_n;

E is a C_2 alkyl substituted with 0-1 R^{17};

R^{17} is =O;

alternatively, C_h is  ;

A^1 is NH_2 or $N=C(R^{20})(R^{21})$;

E is a bond;

A^2 is NHR^{13};

R^{13} is a heterocycle substituted with R^{17}, the heterocycle being selected from pyridine and pyrimidine;

R^{17} is selected from a bond to L_n, $C(=O)NHR^{18}$ and $C(=O)R^{18}$;

R^{18} is a bond to L_n;

R^{24} is selected from the group: $-CO_2R^{25}$, $-OR^{25}$, $-SO_3H$, and $-N(R^{25})_2$; and

R^{25} is independently selected at each occurrence from the group: hydrogen and methyl.

5. A compound according to Claim 4, wherein:

R^{1de} is selected from:



or ;

wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group: NH_2, halogen, NO_2, CN, CF_3, C_1-C_4 alkoxy, C_1-C_6 alkyl, and C_3-C_7 cycloalkyl.

6. A compound according to Claim 2, wherein the compound is selected from the group:

2-(((4-(4-(((3-(2-(2-(3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)propoxy)-ethoxy)ethoxy)propyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)-3-((1-(3-(imidazole-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid;

2-(2-aza-2-((5-(N-(1,3-bis(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)ethyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)propoxy)-ethoxy)ethoxy)propyl)carbamoyl)propyl)carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid;

2-((6-((1-aza-2-(sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-4-(N-(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-ethyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)-amino)propoxy)-ethoxy)ethoxy)propyl)carbamoyl)butanoic acid;

3-((1-(3-(imidazole-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-2-(((4-(4-(((3-(2-(2-(3-(2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-cyclododecyl)-acetylamino)propoxy)ethoxy)ethoxy)propyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)amino)propanoic acid;

2-(6-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl))carbonylamino)hexanoylamino)-3-((1-(3-

(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-propanoic acid;

2-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl))carbonylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid;

[2-[[[5-[carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid]-Glu(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid);

[2-[[[5-[carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid]-Glu-bis-[Glu(2-(6-Aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)];

2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecyl)acetyl-{2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid};

2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecyl)acetyl-Glu{2-(6-Aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid}{2-(6-Aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid};



;

;



;



;



;



;



;



;

2-(((4-(3-(N-(3-(2-(2-(3-(2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecylacetylamino)-6-aminohexanoylamino)propoxy)ethoxy)ethoxy)propyl)-carbamoyl)propoxy)-2,6-dimethylphenyl)-sulfonyl)amino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-propionic acid salt;



;



;

2-({[4-(3-{N-[2-((2R)-3-Sulfo-2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}-propyl)ethyl]carbamoyl}propoxy)-2,6-dimethylphenyl]-sulfonyl}amino)(2S)-3-{1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl)}carbonylamino)propanoic Acid;



;

2-[({4-[4-({[2-((2R)-3-Sulfo-2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]-acetylamino}propyl)ethyl]amino}sulfonyl)phenyl]phenyl}sulfonyl)amino](2S)-3-({1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl)}carbonylamino)propanoic Acid;

(4S)-4-(N-{1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-({1-[3-(2-pyridylamino)propyl](1H-indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxypropyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-(N-{1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-({1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxypropyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-{N-[(1S)-1-(N-{1,3-bis[N-(2-{4-[4-({[(1S)-1-carboxy-2-({1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]propyl}carbamoyl)-3-carboxypropyl]carbamoyl}-4-(6-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}hexanoylamino)butanoic acid;

(4S)-4-(N-{1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-({1-[3-(3,4,5,6-tetrahydropyrimidin-2-ylamino)propyl](1H-

indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxy propyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris (carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-(N-{1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-({1-methyl-3-[3-(2-3,4,5,6-tetrahydropyridylamino)propyl] (1H-indazol-6-yl)}carbonylamino)ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxypropyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-(N-{(1S)-1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-({1-[2-(2-3,4,5,6-tetrahydropyridylamino)ethyl] (1H-indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxy propyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris (carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(2S)-2-{[(2,6-dimethyl-4-{3-[N-(2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetyl-amino}ethyl)carbamoyl]propoxy}phenyl)sulfonyl]amino}-3-({2-[2-(2-3,4,5,6-tetrahydropyridylamino)ethyl](2-hydro-1H-indazol-5-yl)}carbonylamino)propanoic acid;

(4S)-4-{N-[(1S)-1-(N-{2-[({4-[4-({[(1S)-1-carboxy-2-({1-[2-(2-3,4,5,6-tetrahydropyridylamino)ethyl] (1H-indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl)phenyl] phenyl}sulfonyl)amino]ethyl}carbamoyl)-3-

carboxypropyl] carbamoyl}-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxy-methyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-{N-[(1S)-1-(N-{2-[({4-[4-({[(1S)-1-carboxy-2-({1-[3-(3,4,5,6-tetrahydropyrimidin-2-ylamino) propyl](1H-indazol-5-yl)}carbonylamino)ethyl]amino}sulfonyl) phenyl]phenyl}sulfonyl)amino]ethyl}carbamoyl)-3-carboxy propyl]carbamoyl}-4-{2-[1,4,7,10-tetraaza-4,7,10-tris (carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(2S)-3-({3-[(imidazol-2-ylamino) methyl]-1-methyl(1H-indazol-6-yl)}carbonylamino)-2-({[4-(4-{[(2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl) cyclododecyl]acetylamino}ethyl)amino]sulfonyl}phenyl)phenyl]sulfonyl}amino)propanoic acid;

3-[(7-{3-[(6-{[(1E)-1-aza-2-(2-sulfophenyl)vinyl]amino}(3-pyridyl))carbonylamino]propoxy}-1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl))-carbonylamino](2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]-amino}propanoic acid; and

3-{[1-[3-(imidazol-2-ylamino)propyl]-7-(3-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]-acetylamino}propoxy)(1H-indazol-5-yl)]carbonylamino}-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propanoic acid;

or a pharmaceutically acceptable salt form thereof.

7. A kit comprising a compound of Claim 2, or a pharmaceutically acceptable salt form thereof and a pharmaceutically acceptable carrier.

8. A kit according to Claim 7, wherein the kit further comprises one or more ancillary ligands and a reducing agent.

9. A kit according to Claim 8, wherein the ancillary ligands are tricine and TPPTS.

10. A kit according to Claim 8, wherein the reducing agent is tin(II).

11. A diagnostic or therapeutic metallopharmaceutical composition, comprising: a metal, a chelator capable of chelating the metal and a targeting moiety, wherein the targeting moiety is bound to the chelator, is an indazole nonpeptide and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and chelator.

12. A composition according to Claim 11, wherein the metallopharmaceutical is a diagnostic radiopharmaceutical, the metal is a radioisotope selected from the group: ^{99m}Tc, ^{95}Tc, ^{111}In, ^{62}Cu, ^{64}Cu, ^{67}Ga, and ^{68}Ga, and the linking group is present between the targeting moiety and chelator.

13. A composition according to Claim 12, wherein the targeting moiety is an indazole and the receptor is $\alpha_v\beta_3$ or $\alpha_v\beta_5$.

14. A composition according to Claim 13, wherein the radioisotope is ^{99m}Tc or ^{95}Tc, the

radiopharmaceutical further comprises a first ancillary ligand and a second ancillary ligand capable of stabilizing the radiopharmaceutical.

15. A composition according to Claim 14, wherein the radioisotope is ^{99m}Tc.

16. A composition according to Claim 15, wherein the radiopharmaceutical is selected from the group:

^{99m}Tc ((((4-(4-(((3-(2-(2-(3-((6-(diazenido)(3-pyridyl))carbonylamino)propoxy)-ethoxy)ethoxy)propyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)-3-((1-(3-(imidazole-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid) (tricine)(TPPTS);

^{99m}Tc (2-(2-((5-(N-(1,3-bis(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)ethyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)propoxy)-ethoxy)ethoxy)propyl)carbamoyl)propyl)carbamoyl)(2-pyridyl))2-diazenido) (tricine)(TPPTS);

^{99m}Tc (2-((6-(diazenido)(3-pyridyl))carbonylamino)-4-(N-(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-ethyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)-amino)propoxy)-ethoxy)ethoxy)propyl)carbamoyl)butanoic acid) (tricine)(TPPTS);

^{99m}Tc (2-(6-((6-(diazenido)(3-pyridyl))carbonylamino)hexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-propanoic acid) (tricine)(TPPTS);

^{99m}Tc (2-((6-(diazenido)(3-pyridyl))carbonylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid (tricine)(TPPTS);

^{99m}Tc [2-[[[5-[carbonyl]-2-pyridinyl]diazenido]-Glu(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid))(tricine)(TPPTS);

^{99m}Tc ([2-[[[5-[carbonyl]-2-pyridinyl]diazenido]-Glu-bis-[Glu(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)])(tricine)(TPPTS);

17. A composition according to Claim 13, wherein the radioisotope is ^{111}In.

18. A composition according to Claim 17, wherein, the radiopharmaceutical is selected from the group:


;



;



;



;



;



;



; and



.

19. A composition according to Claim 11, wherein the metallopharmaceutical is a therapeutic radiopharmaceutical, the metal is a radioisotope selected from the group: ^{33}P, ^{125}I, ^{186}Re, ^{188}Re, ^{153}Sm, ^{166}Ho, ^{177}Lu, ^{149}Pm, ^{90}Y, ^{212}Bi, ^{103}Pd, ^{109}Pd, ^{159}Gd, ^{140}La, ^{198}Au, ^{199}Au, ^{169}Yb, ^{175}Yb, ^{165}Dy, ^{166}Dy, ^{67}Cu, ^{105}Rh, ^{111}Ag, and ^{192}Ir, the targeting moiety is an indazole nonpeptide and the linking group is present between the targeting moiety and chelator.

20. A composition according to Claim 19, wherein the targeting moiety is an indazole and the receptor is $\alpha_v\beta_3$ or $\alpha_v\beta_5$.

21. A composition according to Claim 20, wherein the radioisotope is ^{153}Sm.

22. A composition according to Claim 20, wherein the radioisotope is ^{177}Lu.

23. A composition according to Claim 22, wherein the radiopharmaceutical is



24. A composition according to Claim 20, wherein the radioisotope is ^{90}Y.

25. A composition according to Claim 24, wherein, the radiopharmaceutical is selected from the group:


;



;



; and



.

26. A composition according to Claim 11, wherein the metallopharmaceutical is a MRI contrast agent, the metal is a paramagnetic metal ion selected from the group: Gd(III), Dy(III), Fe(III), and Mn(II), the targeting moiety is an indazole nonpeptide and the linking group is present between the targeting moiety and chelator.

27. A composition according to Claim 26, wherein the targeting moiety is an indazole and the receptor is $\alpha_v\beta_3$ or $\alpha_v\beta_5$.

28. A composition according to Claim 27, wherein the metal ion is Gd(III).

29. A composition according to Claim 28, wherein the contrast agent is



30. A composition according to Claim 11, wherein the metallopharmaceutical is a X-ray contrast agent, the metal is selected from the group: Re, Sm, Ho, Lu, Pm, Y, Bi, Pd, Gd, La, Au, Au, Yb, Dy, Cu, Rh, Ag, and Ir, the targeting moiety comprises an indazole, the receptor is $\alpha_v\beta_3$ or $\alpha_v\beta_5$, and the linking group is present between the targeting moiety and chelator.

31. A method of treating rheumatoid arthritis in a patient comprising: administering a therapeutic radiopharmaceutical of Claim 19 capable of localizing in new angiogenic vasculature to a patient by injection or infusion.

32. A method of treating cancer in a patient comprising: administering to a patient in need thereof a therapeutic radiopharmaceutical of Claim 19 by injection or infusion.

33. A method of treating restenosis in a patient comprising: administering to a patient, either systemically or locally, a therapeutic radiopharmaceutical of Claim 19 capable of

localizing in the restenotic area and delivering an effective dose of radiation.

34. A method of imaging therapeutic angiogenesis in a patient comprising: (1) administering a diagnostic radiopharmaceutical, a MRI contrast agent, or a X-ray contrast agent of Claim 11 to a patient by injection or infusion; (2) imaging the area of the patient wherein the desired formation of new blood vessels is located.

35. A method of imaging atherosclerosis in a patient comprising: (1) administering a diagnostic radiopharmaceutical, a MRI contrast agent, or a X-ray contrast agent of Claim 11 to a patient by injection or infusion; (2) imaging the area of the patient wherein the atherosclerosis is located.

36. A method of imaging restenosis in a patient comprising: (1) administering a diagnostic radiopharmaceutical, a MRI contrast agent, or a X-ray contrast agent of Claim 11 to a patient by injection or infusion; (2) imaging the area of the patient wherein the restenosis is located.

37. A method of imaging cardiac ischemia in a patient comprising: (1) administering a diagnostic radiopharmaceutical, a MRI contrast agent, or a X-ray contrast agent of Claim 11 to a patient by injection or infusion; (2) imaging the area of the myocardium wherein the ischemic region is located.

38. A method of imaging myocardial reperfusion injury in a patient comprising: (1) administering a diagnostic radiopharmaceutical, a MRI contrast agent, or a X-ray contrast agent of Claim 11 to a patient by injection or infusion; (2) imaging the

area of myocardium wherein the reperfusion injury is located.

39. A method of imaging cancer in a patient comprising: (1) administering a diagnostic radiopharmaceutical of Claim 12 to a patient by injection or infusion; (2) imaging the patient using planar or SPECT gamma scintigraphy, or positron emission tomography.

40. A method of imaging cancer in a patient comprising: (1) administering a MRI contrast agent of Claim 27; and (2) imaging the patient using magnetic resonance imaging.

41. A method of imaging cancer in a patient comprising: (1) administering a X-ray contrast agent of Claim 30; and (2) imaging the patient using X-ray computed tomography.

42. A compound, comprising: a targeting moiety and a surfactant, wherein the targeting moiety is bound to the surfactant, is an indazole nonpeptide, and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and surfactant.

43. A compound according to Claim 42, wherein the linking group is present between the targeting moiety and surfactant.

44. A compound according to Claim 43, wherein the receptor is the integrin $\alpha_v\beta_3$ or $\alpha_v\beta_5$ and the compound is of the formula:

$$(Q)_d\text{-}L_n\text{-}S_f$$

wherein, Q is a independently a compound of Formulae (Ia) or (Ib):



(Ia)



(Ib)

including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein:

X^{1d} is N, CH, C-W^d-X^d-Y^d, or C-L_n;

X^{2d} is N, CH, or C-W^d-X^d-Y^d;

X^{3d} is N, CR^{11d}, or C-W^d-X^d-Y^d;

X^{4d} is N or CR^{11d};

provided that when R^{1d} is R^{1de} then one of X^{1d} and X^{2d} is C-W^d-X^d-Y^d, and when R^{10d} is R^{1de} then X^{3d} is C-W^d-X^d-Y^d;

R^{1d} is selected from: R^{1de}, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_6 alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{1de} is selected from:



or

;

A^d and B^d are independently $-CH_2-$, $-O-$, $-N(R^{2d})-$, or $-C(=O)-$;

A^{1d} and B^{1d} are independently $-CH_2-$ or $-N(R^{3d})-$;

D^d is $-N(R^{2d})-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E^d-F^d is $-C(R^{4d})=C(R^{5d})-$, $-N=C(R^{4d})-$, $-C(R^{4d})=N-$, or $-C(R^{4d})_2C(R^{5d})_2-$;

J^d, K^d, L^d and M^d are independently selected from: $-C(R^{4d})-$, $-C(R^{5d})-$ and $-N-$, provided that at least one of J^d, K^d, L^d and M^d is not $-N-$;

R^{2d} is selected from: H, C_1-C_6 alkyl, (C_1-C_6 alkyl)carbonyl, (C_1-C_6 alkoxy)carbonyl; (C_1-C_6 alkyl)aminocarbonyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, heteroaryl(C_1-C_6 alkyl)carbonyl, heteroarylcarbonyl, aryl(C_1-C_6 alkyl)-, (C_1-C_6 alkyl)carbonyl-, arylcarbonyl, C_1-C_6 alkylsulfonyl, arylsulfonyl, aryl(C_1-C_6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C_1-C_6 alkyl)sulfonyl, aryloxycarbonyl, and aryl(C_1-C_6 alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, CF_3, and nitro;

R^{3d} is selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_1-C_6 alkyl)-;

R^{4d} and R^{5d} are independently selected from: H, C_1-C_4 alkoxy, $NR^{2d}R^{3d}$, halogen, NO_2, CN, CF_3, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, (C_1-C_6

alkyl)carbonyl, (C_1-C_6 alkoxy)carbonyl, arylcarbonyl, or

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, cyano, amino, CF_3, and NO_2;

U^d is selected from:

$-(CH_2)_n{}^d-$,

$-(CH_2)_n{}^d(CR^{7d}=CR^{8d})(CH_2)_m{}^d-$,

$-(CH_2)_n{}^d(C\equiv C)(CH_2)_m{}^d-$,

$-(CH_2)_t{}^dQ(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dO(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dN(R^{6d})(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dC(=O)(CH_2)_m{}^d-$,

$-(CH_2)_n{}^d(C=O)N(R^{6d})(CH_2)_m{}^d-$,

$-(CH_2)_n{}^dN(R^{6d})(C=O)(CH_2)_m{}^d-$, and

$-(CH_2)_n{}^dS(O)_p{}^d(CH_2)_m{}^d-$;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d};

Q^d is selected from 1,2-cycloalkylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,3-pyridinylene, 3,4-pyridinylene, 2,4-pyridinylene, and 3,4-pyridazinylene;

R^{6d} is selected from: H, C_1-C_4 alkyl, or benzyl;

R^{7d} and R^{8d} are independently selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_0-C_6 alkyl)-;

R^{10d} is selected from: H, R^{1de}, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, $N(R^{6d})_2$, halogen, NO_2, CN, CF_3, CO_2R^{17d}, $C(=O)R^{17d}$, $CONR^{17d}R^{20d}$, $-SO_2R^{17d}$, $-SO_2NR^{17d}R^{20d}$, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_6 alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{10de} is selected from: H, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, $N(R^{6d})_2$, halogen, NO_2, CN, CF_3, CO_2R^{17d}, $C(=O)R^{17d}$, $CONR^{17d}R^{20d}$, $-SO_2R^{17d}$, $-SO_2NR^{17d}R^{20d}$, C_1-C_6 alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_6 alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_3-C_7 cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C_4-C_{11} cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, and aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{11d} is selected from H, halogen, CF_3, CN, NO_2, hydroxy, $NR^{2d}R^{3d}$, C_1-C_4 alkyl substituted with 0-1 R^{21d}, C_1-C_4 alkoxy substituted with 0-1 R^{21d}, aryl substituted with 0-1 R^{21d}, aryl(C_1-C_6 alkyl)- substituted with 0-1 R^{21d}, (C_1-C_4 alkoxy)carbonyl substituted with 0-1 R^{21d}, (C_1-C_4 alkyl)carbonyl substituted with 0-1 R^{21d},

C_1-C_4 alkylsulfonyl substituted with 0-1 R^{21d}, and
C_1-C_4 alkylaminosulfonyl substituted with 0-1 R^{21d};

W^d is selected from:
$-(C(R^{12d})_2)_q{}^dC(=O)N(R^{13d})-$, and
$-C(=O)-N(R^{13d})-(C(R^{12d})_2)_q{}^d-$;

X^d is $-C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-$; or

alternatively, W^d and X^d can be taken together to be



;

R^{12d} is selected from H, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, C_4-C_{10} cycloalkylalkyl, (C_1-C_4 alkyl)carbonyl, aryl, and aryl(C_1-C_6 alkyl)-;

R^{13d} is selected from H, C_1-C_6 alkyl, C_3-C_7 cycloalkylmethyl, and aryl(C_1-C_6 alkyl)-;

R^{14d} is selected from:
H, C_1-C_6 alkylthio(C_1-C_6 alkyl)-, aryl(C_1-C_{10} alkylthioalkyl)-, aryl(C_1-C_{10} alkoxyalkyl)-, C_1-C_{10} alkyl, C_1-C_{10} alkoxyalkyl, C_1-C_6 hydroxyalkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl(C_1-C_6 alkyl)-, heteroaryl(C_1-C_6 alkyl)-, aryl, heteroaryl, CO_2R^{17d}, $C(=O)R^{17d}$, and $CONR^{17d}R^{20d}$, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R^{16d} or 0-2 R^{11d};

R^{15d} is selected from:

H, R^{16d}, C_1-C_{10} alkyl, C_1-C_{10} alkoxyalkyl, C_1-C_{10} alkylaminoalkyl, C_1-C_{10} dialkylaminoalkyl, (C_1-C_{10} alkyl)carbonyl, aryl(C_1-C_6 alkyl)carbonyl, C_1-C_{10} alkenyl, C_1-C_{10} alkynyl ,C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl(C_1-C_6 alkyl)-, heteroaryl(C_1-C_6 alkyl)-, aryl, heteroaryl, CO_2R^{17d}, $C(=O)R^{17d}$, $CONR^{17d}R^{20d}$, SO_2R^{17d}, and $SO_2NR^{17d}R^{20d}$, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R^{11d};

Y^d is selected from:

$-COR^{19d}$, $-SO_3H$, $-PO_3H$, tetrazolyl, $-CONHNHSO_2CF_3$, $-CONHSO_2R^{17d}$, $-CONHSO_2NHR^{17d}$, $-NHCOCF_3$, $-NHCONHSO_2R^{17d}$, $-NHSO_2R^{17d}$, $-OPO_3H_2$, $-OSO_3H$, $-PO_3H_2$, $-SO_3H$, $-SO_2NHCOR^{17d}$, $-SO_2NHCO_2R^{17d}$,


,

, and

;

R^{16d} is selected from:

$-N(R^{20d})-C(=O)-O-R^{17d}$,

$-N(R^{20d})-C(=O)-R^{17d}$,

$-N(R^{20d})-C(=O)-NH-R^{17d}$,

$-N(R^{20d})SO_2-R^{17d}$, and

$-N(R^{20d})SO_2-NR^{20d}R^{17d}$;

R^{17d} is selected from:

C_1-C_{10} alkyl optionally substituted with a bond to L_n, C_3-C_{11} cycloalkyl optionally substituted with a bond to L_n, aryl(C_1-C_6 alkyl)- optionally substituted with a bond to L_n, (C_1-C_6 alkyl)aryl optionally substituted with a bond to L_n, heteroaryl(C_1-C_6 alkyl)- optionally substituted with a bond to L_n, (C_1-C_6 alkyl)heteroaryl optionally substituted with a bond to L_n, biaryl(C_1-C_6 alkyl)- optionally substituted with a bond to L_n, heteroaryl optionally substituted with a bond to L_n, aryl optionally substituted with a bond to L_n, biaryl optionally substituted with a bond to L_n, and a bond to L_n, wherein said aryl, biaryl or heteroaryl groups are also optionally substituted with 0-3 substituents selected from the group: C_1-C_4 alkyl, C_1-C_4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF_3, and NO_2;

R^{18d} is selected from:
-H,
$-C(=O)-O-R^{17d}$,
$-C(=O)-R^{17d}$,
$-C(=O)-NH-R^{17d}$,
$-SO_2-R^{17d}$, and
$-SO_2-NR^{20d}R^{17d}$;

R^{19d} is selected from: hydroxy, C_1-C_{10} alkyloxy, C_3-C_{11} cycloalkyloxy, aryloxy, aryl(C_1-C_6 alkoxy)-, C_3-C_{10} alkylcarbonyloxyalkyloxy, C_3-C_{10} alkoxycarbonyloxyalkyloxy, C_2-C_{10} alkoxycarbonylalkyloxy, C_5-C_{10} cycloalkylcarbonyloxyalkyloxy, C_5-C_{10} cycloalkoxycarbonyloxyalkyloxy, C_5-C_{10} cycloalkoxycarbonylalkyloxy, C_7-C_{11} aryloxycarbonylalkyloxy,

C_8-C_{12} aryloxycarbonyloxyalkyloxy,
C_8-C_{12} arylcarbonyloxyalkyloxy,
C_5-C_{10} alkoxyalkylcarbonyloxyalkyloxy,
C_5-C_{10} (5-alkyl-1,3-dioxa-cyclopenten-2-one-yl)methyloxy, C_{10}-C_{14} (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyloxy, and
$(R^{11d})(R^{12d})N$-(C_1-C_{10} alkoxy)-;

R^{20d} is selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_1-C_6 alkyl)-;

R^{21d} is selected from: COOH and NR^{6d}_2;

m^d is 0-4;

n^d is 0-4;

t^d is 0-4;

p^d is 0-2;

q^d is 0-2; and

r^d is 0-2;

with the following provisos:

(1) t^d, n^d, m^d and q^d are chosen such that the number of atoms connecting R^{1d} and Y^d is in the range of 10-14; and

(2) n^d and m^d are chosen such that the value of n^d plus m^d is greater than one unless U^d is $-(CH_2)_t{}^d Q^d (CH_2)_m{}^d$-;

or Q is a peptide selected from the group:



and



;

R^1 is L-valine, D-valine or L-lysine optionally substituted on the ε amino group with a bond to L_n;

R^2 is L-phenylalanine, D-phenylalanine, D-1-naphthylalanine, 2-aminothiazole-4-acetic acid or tyrosine, the tyrosine optionally substituted on the hydroxy group with a bond to L_n;

R^3 is D-valine;

R^4 is D-tyrosine substituted on the hydroxy group with a bond to L_n;

provided that one of R^1 and R^2 in each Q is substituted with a bond to L_n, and further provided that when R^2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine;

provided that at least one Q is a compound of Formula Ia or Ib;

d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

L_n is a linking group having the formula: $((W)_h-(CR^6R^7)_g)_x-(Z)_k-((CR^{6a}R^{7a})_{g'}-(W)_{h'})_{x'}$;

W is independently selected at each occurrence from the group: O, S, NH, NHC(=O), C(=O)NH, $NR^8C(=O)$, C(=O)NR^8, C(=O), C(=O)O, OC(=O), NHC(=S)NH, NHC(=O)NH, SO_2, SO_2NH, $(OCH_2CH_2)_{20-200}$, $(CH_2CH_2O)_{20-200}$, $(OCH_2CH_2CH_2)_{20-200}$, $(CH_2CH_2CH_2O)_{20-200}$, and $(aa)_{t'}$;

aa is independently at each occurrence an amino acid;

Z is selected from the group: aryl substituted with 0-3 R^{10}, C_{3-10} cycloalkyl substituted with 0-3 R^{10}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{10};

R^6, R^{6a}, R^7, R^{7a}, and R^8 are independently selected at each occurrence from the group: H, =O, COOH, SO_3H, PO_3H, C_1-C_5 alkyl substituted with 0-3 R^{10}, aryl substituted with 0-3 R^{10}, benzyl substituted with 0-3 R^{10}, and C_1-C_5 alkoxy substituted with 0-3 R^{10}, $NHC(=O)R^{11}$, $C(=O)NHR^{11}$, $NHC(=O)NHR^{11}$, NHR^{11}, R^{11}, and a bond to S_f;

R^{10} is independently selected at each occurrence from the group: a bond to S_f, $COOR^{11}$, $C(=O)NHR^{11}$, $NHC(=O)R^{11}$, OH, NHR^{11}, SO_3H, PO_3H, $-OPO_3H_2$, $-OSO_3H$, aryl substituted with 0-3 R^{11}, C_{1-5} alkyl substituted with 0-1 R^{12}, C_{1-5} alkoxy substituted with 0-1 R^{12}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R^{11};

R^{11} is independently selected at each occurrence from the group: H, alkyl substituted with 0-1 R^{12}, aryl substituted with 0-1 R^{12}, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-1 R^{12}, C_{3-10} cycloalkyl substituted with 0-1 R^{12}, and a bond to S_f;

R^{12} is a bond to S_f;

k is selected from 0, 1, and 2;
h is selected from 0, 1, and 2;
h' is selected from 0, 1, and 2;
g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
g' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
t' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
x is selected from 0, 1, 2, 3, 4, and 5;
x' is selected from 0, 1, 2, 3, 4, and 5;

S_f is a surfactant which is a lipid or a compound of the formula:  ;

A^9 is selected from the group: OH and OR^{27};

A^{10} is OR^{27};

R^{27} is $C(=O)C_{1-20}$ alkyl;

E^1 is C_{1-10} alkylene substituted with 1-3 R^{28};

R^{28} is independently selected at each occurrence from the group: R^{30}, $-PO_3H-R^{30}$, =O, $-CO_2R^{29}$, $-C(=O)R^{29}$, $-C(=O)N(R^{29})_2$, $-CH_2OR^{29}$, $-OR^{29}$, $-N(R^{29})_2$, C_1-C_5 alkyl, and C_2-C_4 alkenyl;

R^{29} is independently selected at each occurrence from the group: R^{30}, H, C_1-C_6 alkyl, phenyl, benzyl, and trifluoromethyl;

R^{30} is a bond to L_n;

and a pharmaceutically acceptable salt thereof.

45. A compound according to Claim 44, wherein the compound is of the formula:

$$Q\text{-}L_n\text{-}S_f$$

wherein: Q is a compound of Formula (Ia) or (Ib):



(Ia)



(Ib)

R^{1de} is selected from:













or



;

A^d and B^d are independently $-CH_2-$, $-O-$, $-N(R^{2d})-$, or $-C(=O)-$;

A^{1d} and B^{1d} are independently $-CH_2-$ or $-N(R^{3d})-$;

D^d is $-N(R^{2d})-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E^d-F^d is $-C(R^{4d})=C(R^{5d})-$, $-N=C(R^{4d})-$, $-C(R^{4d})=N-$, or $-C(R^{4d})_2C(R^{5d})_2-$;

J^d, K^d, L^d and M^d are independently selected from: $-C(R^{4d})-$, $-C(R^{5d})-$ and $-N-$, provided that at least one of J^d, K^d, L^d and M^d is not $-N-$;

R^{2d} is selected from: H, C_1-C_6 alkyl, (C_1-C_6 alkyl)carbonyl, (C_1-C_6 alkoxy)carbonyl, C_1-C_6 alkylaminocarbonyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, heteroaryl(C_1-C_6 alkyl)carbonyl, heteroarylcarbonyl, aryl(C_1-C_6 alkyl)-, (C_1-C_6 alkyl)carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(C_1-C_6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C_1-C_6 alkyl)sulfonyl, aryloxycarbonyl, and aryl(C_1-C_6 alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group: C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, CF_3, and nitro;

R^{3d} is selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_1-C_6 alkyl)-;

R^{4d} and R^{5d} are independently selected from: H, C_1-C_4 alkoxy, $NR^{2d}R^{3d}$, halogen, NO_2, CN, CF_3, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, C_2-C_7 alkylcarbonyl, and arylcarbonyl or

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms

to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, cyano, amino, CF_3, and NO_2;

U^d is selected from:

$-(CH_2)_n^d-$,

$-(CH_2)_n^d(CR^{7d}=CR^{8d})(CH_2)_m^d-$,

$-(CH_2)_t^d Q^d (CH_2)_m^d-$,

$-(CH_2)_n^d O(CH_2)_m^d-$,

$-(CH_2)_n^d N(R^{6d})(CH_2)_m^d-$,

$-(CH_2)_n^d C(=O)(CH_2)_m^d-$, and

$-(CH_2)_n^d S(O)_p^d (CH_2)_m^d-$;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d};

Q^d is selected from 1,2-phenylene, 1,3-phenylene, 2,3-pyridinylene, 3,4-pyridinylene, and 2,4-pyridinylene;

R^{6d} is selected from: H, C_1-C_4 alkyl, and benzyl;

R^{7d} and R^{8d} are independently selected from: H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_4-C_{11} cycloalkylalkyl, aryl, aryl(C_1-C_6 alkyl)-, and heteroaryl(C_0-C_6 alkyl)-;

W^d is $-C(=O)-N(R^{13d})-(C(R^{12d})_2)_q^d-$;

X^d is $-C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-$;

alternatively, W^d and X^d can be taken together to be



;

R^{12d} is H or C_1-C_6 alkyl;

Y^d is selected from:

$-COR^{19d}$, $-SO_3H$,



,



, and



;

Z is selected from the group: aryl substituted with 0-1 R^{10}, C_{3-10} cycloalkyl substituted with 0-1 R^{10}, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-1 R^{10};

R^6, R^{6a}, R^7, R^{7a}, and R^8 are independently selected at each occurrence from the group: H, =O, COOH, SO_3H, C_1-C_5 alkyl substituted with 0-1 R^{10}, aryl substituted with 0-1 R^{10}, benzyl substituted with 0-1 R^{10}, and C_1-C_5 alkoxy substituted with 0-1 R^{10}, $NHC(=O)R^{11}$, $C(=O)NHR^{11}$, $NHC(=O)NHR^{11}$, NHR^{11}, R^{11}, and a bond to S_f;

k is 0 or 1;

S_f is a surfactant which is a lipid or a compound of the formula:  ;

A^9 is OR^{27};

A^{10} is OR^{27};

R^{27} is $C(=O)C_{1-15}$ alkyl;

E^1 is C_{1-4} alkylene substituted with 1-3 R^{28};

R^{28} is independently selected at each occurrence from the group: R^{30}, $-PO_3H-R^{30}$, =O, $-CO_2R^{29}$, $-C(=O)R^{29}$, $-CH_2OR^{29}$, $-OR^{29}$, and C_1-C_5 alkyl;

R^{29} is independently selected at each occurrence from the group: R^{30}, H, C_1-C_6 alkyl, phenyl, and benzyl;

R^{30} is a bond to L_n;

and a pharmaceutically acceptable salt thereof.

46. A compound according to Claim 45, wherein the present invention provides a compound selected from the group:

DPPE-2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid-dodecanoate conjugate;

ω-amino-PEG_{3400}-2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid; and

ω-amino-PEG_{3400}-Glu-(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)-propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)$_2$.

47. An ultrasound contrast agent composition, comprising:
(a) a compound of Claim 44, comprising: an indazole that binds to the integrin $\alpha_v\beta_3$ or $\alpha_v\beta_5$ a surfactant and a linking group between the indazole and the surfactant;
(b) a parenterally acceptable carrier; and,
(c) an echogenic gas.

48. An ultrasound contrast agent composition of Claim 47, further comprising: 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine.

49. An ultrasound contrast agent composition of Claim 48, wherein the echogenic gas is a C_{2-5} perfluorocarbon.

50. A method of imaging cancer in a patient comprising: (1) administering, by injection or infusion, a ultrasound contrast agent composition of Claim 44 to a patient; and (2) imaging the patient using sonography.

51. A method of imaging therapeutic angiogenesis in a patient comprising: (1) administering, by injection or infusion, an ultrasound contrast agent composition of Claim 42 to a patient; (2) imaging the area of the patient wherein the desired formation of new blood vessels is located.

52. A method of imaging atherosclerosis in a patient comprising: (1) administering, by injection or infusion, an ultrasound contrast agent composition of Claim 42 to a patient; (2) imaging the area of the patient wherein the atherosclerosis is located.

53. A method of imaging restenosis in a patient comprising: (1) administering, by injection or infusion, an ultrasound contrast agent composition of Claim 42 to a patient; (2) imaging the area of the patient wherein the restenosis is located.

54. A method of imaging cardiac ischemia in a patient comprising: (1) administering, by injection or infusion, an ultrasound contrast agent composition of Claim 42 to a patient; (2) imaging the area of the myocardium wherein the ischemic region is located.

55. A method of imaging myocardial reperfusion injury in a patient comprising: (1) administering, by injection or infusion, an ultrasound contrast agent composition of Claim 42 to a patient; (2) imaging the area of myocardium wherein the reperfusion injury is located.

56. A therapeutic radiopharmaceutical composition, comprising:
(a) a therapeutic radiopharmaceutical of Claim 19; and,

(b) a parenterally acceptable carrier.

57. A diagnostic pharmaceutical composition, comprising:
(a) a diagnostic radiopharmaceutical, a MRI contrast agent, or a X-ray contrast agent of Claim 11; and,
(b) a parenterally acceptable carrier.

58. A kit for treating cancer, comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and at least one agent selected from the group consisting of a chemotherapeutic agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

59. A kit according to claim 58 wherein said kit comprises a plurality of separate containers, wherein at least one of said containers contains a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and at least another of said containers contains one or more agents selected from the group consisting of a chemotherapeutic agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

60. A kit according to Claim 58, wherein the chemotherapeutic agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine,

vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, formestane, interferon-alpha, interferon-2 alpha, interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.

61. A kit according to Claim 58, wherein the chemotherapeutic agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, and lisuride.

62. A kit according to Claim 58 wherein the chemotherapeutic agent is selected from the group consisting of oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, and formestane.

63. A kit according to Claim 58 wherein the chemotherapeutic agent is selected from the group consisting of interferon-alpha, interferon-2 alpha,

interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.

64. A kit according to Claim 58, wherein radiosensitizer agent is selected from the group consiting of 2-(3-nitro-1,2,4-triazol-1-yl)-N-(2-methoxyethyl)acetamide, N-(3-nitro-4-quinolinyl)-4-morpholinecarboxamidine, 3-amino-1,2,4-benzotriazine-1,4-dioxide, N-(2-hydroxyethyl)-2-nitroimidazole-1-acetamide, 1-(2-nitroimidazol-1-yl)-3-(1-piperidinyl)-2-propanol, and 1-(2-nitro-1-imidazolyl)-3-(1-aziridino)-2-propanol.

65. A therapeutic metallopharmaceutical composition according to claim 11, wherein the metallopharmaceutical is a therapeutic radiopharmaceutical, further comprising at least one agent selected from the group consisting of a chemotherapeutic agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof.

66. A therapeutic metallopharmaceutical composition according to claim 65, wherein the chemotherapeutic agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol,

tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, formestane, interferon-alpha, interferon-2 alpha, interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.

Sub B2

67. A therapeutic metallopharmaceutical composition according to claim 65, wherein radiosensitizer agent is selected from the group consiting of 2-(3-nitro-1,2,4-triazol-1-yl)-N-(2-methoxyethyl)acetamide, N-(3-nitro-4-quinolinyl)-4-morpholinecarboxamidine, 3-amino-1,2,4-benzotriazine-1,4-dioxide, N-(2-hydroxyethyl)-2-nitroimidazole-1-acetamide, 1-(2-nitroimidazol-1-yl)-3-(1-piperidinyl)-2-propanol, and 1-(2-nitro-1-imidazolyl)-3-(1-aziridino)-2-propanol.

68. A method of treating cancer in a patient comprising: administering to a patient in need thereof a therapeutic radiopharmaceutical of Claim 19 or a pharmaceutically acceptable salt thereof, and at least one agent selected from the group consisting of a chemotherapeutic agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof.

69. A method of treating cancer according to claim 68, wherein the administration is by injection or infusion.

70. A method according to claim 68 wherein administering the therapeutic radiopharmaceutical and agent is concurrent.

71. A method according to claim 68 wherein administering the therapeutic radiopharmaceutical and agent is sequential.

72. A method according to claim 68 wherein the cancer is selected from the group consisting of carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate,thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, and neuroblastomas.

73. A method according to claim 68 wherein the chemotherapeutic agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, formestane, interferon-alpha, interferon-2 alpha, interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.

74. A method according to claim 68 wherein the radiosensitizer agent is selected from the group consiting of 2-(3-nitro-1,2,4-triazol-1-yl)-N-(2-methoxyethyl)acetamide, N-(3-nitro-4-quinolinyl)-4-morpholinecarboxamidine, 3-amino-1,2,4-benzotriazine-1,4-dioxide, N-(2-hydroxyethyl)-2-nitroimidazole-1-acetamide, 1-(2-nitroimidazol-1-yl)-3-(1-piperidinyl)-2-propanol, and 1-(2-nitro-1-imidazolyl)-3-(1-aziridino)-2-propanol.

75. A process for the preparation of diagnostic or therapeutic metallopharmaceutical composition, said process comprising generating a macrostructure from a plurality of molecular components wherein the plurality of components includes a targeting moiety and a chelator, wherein the targeting moiety is a indazole nonpeptide, which is bound to the chelator, and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and chelator.

add B3